Supernus Pharmaceuticals Files 8-K Report
Ticker: SUPN · Form: 8-K · Filed: 2025-02-04T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K on Feb 4, 2025, covering 'Other Events' and financials. Details pending.
AI Summary
On February 4, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing serves as an official notification to investors and the public about significant company events or financial updates from Supernus Pharmaceuticals, Inc.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate disclosure of negative events or significant financial changes.
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- February 4, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are detailed in this 8-K filing?
The provided excerpt does not specify the 'Other Events' beyond listing the item information category.
Are there any new financial statements or exhibits attached to this filing?
The filing lists 'Financial Statements and Exhibits' as an item information category, but the content of these is not detailed in the excerpt.
What is the principal business address of Supernus Pharmaceuticals, Inc.?
The principal executive offices are located at 9715 Key West Ave, Rockville, MD 20850.
What is the SEC file number for Supernus Pharmaceuticals, Inc.?
The SEC file number for Supernus Pharmaceuticals, Inc. is 001-35518.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 4, 2025.
Filing Stats: 484 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-02-04 16:23:54
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto
Filing Documents
- supn-20250204.htm (8-K) — 28KB
- ex-991xonapgopressrelease.htm (EX-99.1) — 53KB
- image_0a.jpg (GRAPHIC) — 5KB
- 0001356576-25-000004.txt ( ) — 221KB
- supn-20250204.xsd (EX-101.SCH) — 2KB
- supn-20250204_lab.xml (EX-101.LAB) — 21KB
- supn-20250204_pre.xml (EX-101.PRE) — 12KB
- supn-20250204_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On February 4, 2025, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") issued a press release announcing the receipt of the final approval from the U.S. Food and Drug Administration (FDA) for SPN-830 (ONAPGO) for the continuous treatment of motor fluctuations (OFF episodes) in people with Parkinson's disease (PD) not adequately controlled with oral levodopa and one or more adjunct PD medications. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 — Press Release Dated February 4, 2025 furnished as an Exhibit pursuant to Item 8.01 hereof. Exhibit 104 — The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: February 4, 2025 By: /s/ Timothy Dec Timothy Dec Senior Vice-President and Chief Financial Officer 3